2026OCEANIC-STROKEIn 12,327 patients with non-cardioembolic stroke or high-risk TIA, asundexian reduced recurrent ischemic stroke compared with placebo.
2024ANNEXA-Ifactor Xa reversalIn 530 patients with factor Xa inhibitor-associated intracerebral haemorrhage, andexanet alfa improved haemostatic efficacy compared with usual care.
2020CARAVAGGIOVenous thromboembolismIn 1,170 patients with cancer-associated venous thromboembolism, apixaban was non-inferior to dalteparin for recurrent VTE, without excess major bleeding.
2019AUGUSTUSAF + PCIIn 4,614 patients with AF and recent ACS or PCI, apixaban without aspirin reduced major or clinically relevant bleeding compared with warfarin-based triple therapy.
2017COMPASSChronic atherosclerosisIn 27,395 patients with stable coronary or peripheral artery disease, low-dose rivaroxaban plus aspirin reduced cardiovascular death, stroke or MI compared with aspirin alone.
2014PEITHOPulmonary embolismIn 1,006 patients with intermediate-risk pulmonary embolism, tenecteplase reduced haemodynamic decompensation but increased major and intracranial bleeding compared with heparin alone.
2014ULTIMAPulmonary embolismIn 59 patients with intermediate-risk pulmonary embolism and right-ventricular dilatation, ultrasound-assisted catheter-directed thrombolysis reversed the right-ventricular-to-left-ventricular diameter ratio at 24 hours more than unfractionated heparin alone.
2013WOESTAF + PCIIn 573 patients on oral anticoagulation undergoing PCI, clopidogrel without aspirin reduced bleeding compared with triple therapy.
2013AMPLIFYVenous thromboembolismIn 5,395 patients with acute venous thromboembolism, apixaban was non-inferior to conventional heparin–warfarin therapy for recurrent VTE, with far less major bleeding.
2013HOKUSAI-VTEVenous thromboembolismIn 8,240 patients with acute venous thromboembolism after initial heparin, once-daily edoxaban was non-inferior for recurrent symptomatic venous thromboembolism and caused less clinically relevant bleeding than warfarin.
2012EINSTEIN-PEPulmonary embolismIn 4,832 patients with acute symptomatic pulmonary embolism, single-drug oral rivaroxaban was non-inferior for recurrent venous thromboembolism and halved major bleeding compared with enoxaparin followed by a vitamin K antagonist.